» Articles » PMID: 29403482

B and T Cell Phenotypic Profiles of African HIV-Infected and HIV-Exposed Uninfected Infants: Associations with Antibody Responses to the Pentavalent Rotavirus Vaccine

Abstract

We examined associations between B and T cell phenotypic profiles and antibody responses to the pentavalent rotavirus vaccine (RV5) in perinatally HIV-infected (PHIV) infants on antiretroviral therapy and in HIV-exposed uninfected (PHEU) infants enrolled in International Maternal Pediatric Adolescent AIDS Clinical Trials P1072 study (NCT00880698). Of 17 B and T cell subsets analyzed, PHIV and PHEU differed only in the number of CD4+ T cells and frequency of naive B cells, which were higher in PHEU than in PHIV. In contrast, the B and T cell phenotypic profiles of PHIV and PHEU markedly differed from those of geographically matched contemporary HIV-unexposed infants. The frequency of regulatory T and B cells (Treg, Breg) of PHIV and PHEU displayed two patterns of associations: FOXP3+ CD25+ Treg positively correlated with CD4+ T cell numbers; while TGFβ+ Treg and IL10+ Treg and Breg positively correlated with the frequencies of inflammatory and activated T cells. Moreover, the frequencies of activated and inflammatory T cells of PHIV and PHEU positively correlated with the frequency of immature B cells. Correlations were not affected by HIV status and persisted over time. PHIV and PHEU antibody responses to RV5 positively correlated with CD4+ T cell counts and negatively with the proportion of immature B cells, similarly to what has been previously described in chronic HIV infection. Unique to PHIV and PHEU, anti-RV5 antibodies positively correlated with CD4+/CD8+FOXP3+CD25+% and negatively with CD4+IL10+% Tregs. In conclusion, PHEU shared with PHIV abnormal B and T cell phenotypic profiles. PHIV and PHEU antibody responses to RV5 were modulated by typical HIV-associated immune response modifiers except for the association between CD4+/CD8+FOXP3+CD25+Treg and increased antibody production.

Citing Articles

Infectivity and Immunogenicity of Live-Attenuated Respiratory Syncytial Virus Vaccines in Human Immunodeficiency Virus-Exposed Uninfected Children.

Kelly M, Cunningham C, McFarland E, Giganti M, Lindsey J, Perlowski C Open Forum Infect Dis. 2024; 11(12):ofae679.

PMID: 39610407 PMC: 11604081. DOI: 10.1093/ofid/ofae679.


Frequency of B-Cell Subpopulations in Low Responders in Comparison with High Responders to Hepatitis B Vaccine Among Health Care Workers.

Saleh Z, Mehdipour F, Ataollahi M, Ali-Hassanzadeh M, Kabelitz D, Kalantar K Curr Microbiol. 2023; 80(9):296.

PMID: 37488238 DOI: 10.1007/s00284-023-03367-0.


Treatment with Antiviral Drugs Will Significantly Inhibit the HIV-1 RNA POL Gene Expression and Viral Load in AIDS Patients.

Shi P, Wang X, Su M, Meng J, Wang H, Fan W Dis Markers. 2023; 2023:9910542.

PMID: 37091892 PMC: 10121356. DOI: 10.1155/2023/9910542.


T-Cell Responses after Rotavirus Infection or Vaccination in Children: A Systematic Review.

Laban N, Goodier M, Bosomprah S, Simuyandi M, Chisenga C, Chilyabanyama O Viruses. 2022; 14(3).

PMID: 35336866 PMC: 8951614. DOI: 10.3390/v14030459.


Vaccines for preventing rotavirus diarrhoea: vaccines in use.

Bergman H, Henschke N, Hungerford D, Pitan F, Ndwandwe D, Cunliffe N Cochrane Database Syst Rev. 2021; 11:CD008521.

PMID: 34788488 PMC: 8597890. DOI: 10.1002/14651858.CD008521.pub6.


References
1.
Hygino J, Lima P, Filho R, Silva A, Saramago C, Andrade R . Altered immunological reactivity in HIV-1-exposed uninfected neonates. Clin Immunol. 2008; 127(3):340-7. DOI: 10.1016/j.clim.2008.01.020. View

2.
Punkosdy G, Blain M, Glass D, Lozano M, OMara L, Dudley J . Regulatory T-cell expansion during chronic viral infection is dependent on endogenous retroviral superantigens. Proc Natl Acad Sci U S A. 2011; 108(9):3677-82. PMC: 3048095. DOI: 10.1073/pnas.1100213108. View

3.
Hygino J, Vieira M, Guillermo L, Silva-Filho R, Saramago C, Lima-Silva A . Enhanced Th17 phenotype in uninfected neonates born from viremic HIV-1-infected pregnant women. J Clin Immunol. 2010; 31(2):186-94. DOI: 10.1007/s10875-010-9485-3. View

4.
Levin M, Lindsey J, Kaplan S, Schimana W, Lawrence J, McNeal M . Safety and immunogenicity of a live attenuated pentavalent rotavirus vaccine in HIV-exposed infants with or without HIV infection in Africa. AIDS. 2016; 31(1):49-59. PMC: 5287361. DOI: 10.1097/QAD.0000000000001258. View

5.
Lederman M, Funderburg N, Sekaly R, Klatt N, Hunt P . Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol. 2013; 119:51-83. PMC: 4126613. DOI: 10.1016/B978-0-12-407707-2.00002-3. View